The Europeans Medicines Agency (EMA) was met with a backlash of criticism following the restrictions made in 2013, with a number of experts and academics backing the criticism. Evidence supporting the use of hydroxyethyl starch (HES) was also bought into question during 2014.
In the years that followed the decision to restrict the use of HES, supporting evidence grew leading to a review of the decision in the hope of banning HES from both the European and US markets.Timeline homepage
Alternatively login via
Back to epgonline.org